Key facts
- Vima Therapeutics’s last known valuation is $118.0M (Mar 2026).
- It has raised $100.0M; the latest was Early Stage VC ($100.0M) in Mar 2026.
- Notable investors include Frazier Healthcare Partners, Atlas Venture, Access Biotechnology, Canaan Creative.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Vima Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vima Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vima Therapeutics
Developer of oral therapeutics designed for the treatment of movement disorders. The company offers clinical-stage biotechnology research focused on targeting the underlying causes of dystonia through advanced pharmacological approaches, providing patients with improved motor control, enhanced treatment efficacy, and better tolerability while addressing the neurological mechanisms responsible for involuntary muscle contractions.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 20
- Website
- vimatx.com/
- Ownership
- Privately Held (backing)
Vima Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vima Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vima Therapeutics in its N-PORT filings yet. We sweep new filings monthly.